The 2024 CAIO Report

CMOs Leaning on GenAI for Market Research, Even as ROI Dips

Nearly all chief marketing officers (CMOs) agree that GenAI is critical for customer experience and streamlining marketing and insights. In just three months, there has been a 24% increase in CMOs entrusting GenAI tools for market research and insights. However, despite fewer firms reporting very positive return on investment (ROI) from GenAI, data from 60 CMOs reveals that many firms plan to increase their GenAI investments in the next year. This edition of the CAIO Project details the latest in this changing ecosystem.

Get Unlimited Access
Complete the form below for free, unlimited access to all our Data Studies, Trackers, and MonitorEdge reports.

Thank you for registering. Please confirm your email to view all our Trackers.

    yesSubscribe to our daily newsletter, PYMNTS Today

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Most surveyed chief marketing officers (CMOs) from firms generating at least $1 billion in annual revenue report that GenAI’s most significant use case for their businesses is market research and insights. As of July, CMOs used GenAI more to improve customer experiences and increase the speed of their own decision-making. Despite data showing falling return on investment (ROI) expectations related to GenAI, CMOs plan to increase their investments in this technology in the near future. However, implementation costs are not just financial. CMOs report concerns about organizational issues stemming from implementing GenAI.

    Limited ROI is no deterrent to CFOs’ commitments to increase GenAI investments for complex strategic tasks in the future.

    Source: PYMNTS Intelligence
    CMOs Leaning on GenAI For Market Research, Even As ROI Dips, September 2024
    N = 60: Complete CMO respondents, fielded July 10, 2024 – July 19, 2024



    While CMOs are aware of GenAI’s potential, they may be slower to implement it strategically and instead focus on making routine tasks efficient.

    These are just some of the findings detailed in “CMOs Leaning on GenAI For Market Research, Even As ROI Dips,” the fifth edition of PYMNTS Intelligence’s 2024 CAIO Project. This series offers a monthly recap of the players and innovators using GenAI to revolutionize how they manage key parts of their businesses. This edition examines CMOs’ evolving perceptions of GenAI and draws on insights from 60 CMOs from U.S. firms that generated at least $1 billion in revenue last year, conducted from July 10 to July 19.

    Key Findings

    More and more, the most popular specific uses of GenAI among CMOs are to streamline creative processes and improve customer experiences.

    GenAI’s benefits for market research and insights are catching on among CMOs like wildfire. Almost uniformly, CMOs agree that their most important use of the technology is to understand their customers’ needs, preferences and behaviors. As of July, more than 9 in 10 CMOs said they used GenAI for actions in the category of market research and insights. This marks a 24% increase in CMOs using the technology for market research and insights since we last asked them in April. Similarly, more than 8 in 10 said they used it to improve customer experience.

    CMOs’ responses align with a growing agreement among executives on GenAI’s precise benefits. Its most popular specific uses include creating content and streamlining access to information for employees and customers. For each, 60% of CMOs said they had used the technology in that way. The data suggests that marketing research and insights teams lean more on the technology to meet internal and external needs.

    CMOs are optimistic about GenAI’s future and plan to increase their investments in it despite lower perceptions of ROI.

    CMOs’ perceptions of the significance of GenAI have notably evolved from when we last surveyed them in April. Now, 55% of CMOs plan to increase their investments in the technology — a 22% increase in just a few months. This uptick reflects what nearly all CMOs agree on: GenAI will help improve customer experiences, the speed of their decision-making and streamline operations. The data suggests that in just a short time, CMOs have gained confidence in embracing the capabilities of GenAI for the future of their businesses.

    The shift in CMOs’ perception comes despite steadily declining perceptions of ROI from GenAI. Among middle-market firms, the share of CMOs reporting very positive ROI generated from GenAI was 23% three months ago and just 8.3% now. This decline in perceived ROI reflects a change in considering the technology as a short-term moneymaker in favor of a long-term strategy play. GenAI requires an initial investment from CMOs, both in acquiring an existing application and integrating it into their businesses’ workflows. The data suggests that CMOs may have reached the maximum level of return possible based on the applications they are currently using with GenAI. Consequently, CMOs are ready to increase their budget to increase their capabilities.

    CMOs are increasingly concerned about the organizational issues that implementing GenAI causes.

    CMOs may be committed to investing more in GenAI, but they are also dealing with the ripple effects of implementation. Their responses from April show that some of the biggest issues they faced with the technology have declined. In April, 70% of CMOs said they were unfamiliar with how the technology works, for example. Three months later, 63% say so, indicating CMOs are becoming more familiar with GenAI. CMOs also note reduced errors and output issues related to rolling out GenAI. This data suggests that CMOs are learning how to effectively integrate the technology.

    However, while CMOs are more confident about working with the technology directly, its impact on other relationships is entering the spotlight. CMOs are 51% more concerned about the organizational issues GenAI causes than in April 2024. Their rising concerns include relying on vendors for GenAI and the transparency and bias this may produce as a result. CMOs may be uniquely concerned about how the technology affects the stream of information under their supervision.

    Conclusion

    Surveyed CMOs agree that continuing to increase their GenAI investments is critical for running their businesses. In three short months, CMOs increased their use of the technology for market research and insights by 24%. Their fervor for it remains constant despite falling ROI from this technology. While CMOs have more confidence in GenAI’s capabilities, they still face mounting organizational issues from its roll out.

    Methodology

    CMOs Leaning on GenAI for Market Research, Even as ROI Dips,” is based on a survey of U.S. CMOs conducted from July 10 to July 19. The report explores the impact and perceptions of GenAI implementation for CMOs. Our sample included interviews with 60 CMOs from U.S. firms that generated at least $1 billion in revenue last year.

    About

    PYMNTS INTELLIGENCE

    PYMNTS Intelligence is a leading global data and analytics platform that uses proprietary data and methods to provide actionable insights on what’s now and what’s next in payments, commerce and the digital economy. Its team of data scientists include leading economists, econometricians, survey experts, financial analysts and marketing scientists with deep experience in the application of data to the issues that define the future of the digital transformation of the global economy. This multi-lingual team has conducted original data collection and analysis in more than three dozen global markets for some of the world’s leading publicly traded and privately held firms.

    The PYMNTS Intelligence team that produced this report:
    Scott Murray: SVP and Head of Analytics
    Yvonni Markaki, PhD: Senior Analyst
    Anna Sofia Martin: Senior Writer


    We are interested in your feedback on this report. If you have questions or comments, or if you would like to subscribe to this report, please email us at feedback@pymnts.com.

    Disclaimer

    The 2024 CAIO Report may be updated periodically. While reasonable efforts are made to keep the content accurate and up to date, PYMNTS MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, REGARDING THE CORRECTNESS, ACCURACY, COMPLETENESS, ADEQUACY, OR RELIABILITY OF OR THE USE OF OR RESULTS THAT MAY BE GENERATED FROM THE USE OF THE INFORMATION OR THAT THE CONTENT WILL SATISFY YOUR REQUIREMENTS OR EXPECTATIONS. THE CONTENT IS PROVIDED “AS IS” AND ON AN “AS AVAILABLE” BASIS. YOU EXPRESSLY AGREE THAT YOUR USE OF THE CONTENT IS AT YOUR SOLE RISK. PYMNTS SHALL HAVE NO LIABILITY FOR ANY INTERRUPTIONS IN THE CONTENT THAT IS PROVIDED AND DISCLAIMS ALL WARRANTIES WITH REGARD TO THE CONTENT, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT AND TITLE. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF CERTAIN WARRANTIES, AND, IN SUCH CASES, THE STATED EXCLUSIONS DO NOT APPLY. PYMNTS RESERVES THE RIGHT AND SHOULD NOT BE LIABLE SHOULD IT EXERCISE ITS RIGHT TO MODIFY, INTERRUPT, OR DISCONTINUE THE AVAILABILITY OF THE CONTENT OR ANY COMPONENT OF IT WITH OR WITHOUT NOTICE.
    PYMNTS SHALL NOT BE LIABLE FOR ANY DAMAGES WHATSOEVER, AND, IN PARTICULAR, SHALL NOT BE LIABLE FOR ANY SPECIAL, INDIRECT, CONSEQUENTIAL, OR INCIDENTAL DAMAGES, OR DAMAGES FOR LOST PROFITS, LOSS OF REVENUE, OR LOSS OF USE, ARISING OUT OF OR RELATED TO THE CONTENT, WHETHER SUCH DAMAGES ARISE IN CONTRACT, NEGLIGENCE, TORT, UNDER STATUTE, IN EQUITY, AT LAW, OR OTHERWISE, EVEN IF PYMNTS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
    SOME JURISDICTIONS DO NOT ALLOW FOR THE LIMITATION OR EXCLUSION OF LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, AND IN SUCH CASES SOME OF THE ABOVE LIMITATIONS DO NOT APPLY. THE ABOVE DISCLAIMERS AND LIMITATIONS ARE PROVIDED BY PYMNTS AND ITS PARENTS, AFFILIATED AND RELATED COMPANIES, CONTRACTORS, AND SPONSORS, AND EACH OF ITS RESPECTIVE DIRECTORS, OFFICERS, MEMBERS, EMPLOYEES, AGENTS, CONTENT COMPONENT PROVIDERS, LICENSORS, AND ADVISERS.
    Components of the content original to and the compilation produced by PYMNTS is the property of PYMNTS and cannot be reproduced without its prior written permission.